ALKERMES PLC. (ALKS)
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Global Ship Lease Announces Results of 2026 Annual Meeting of Shareholders
Clorox Announces Simplified Operating Structure to Improve Execution and Accelerate Growth
ICON Schedules First Quarter 2026 Earnings Conference Call
Urban Edge Properties Invites You to Join Its Second Quarter 2026 Earnings Conference Call
ADT Joins Board of Directors of the Connectivity Standards Alliance, Reinforcing Its Role in Shaping the Future of the Connected Home
National Healthcare Properties Announces Preliminary Results of its Series A and Series B Preferred Stock Self Tender Offers
Rumble Closes Acquisition of Northern Data
Kimco Realty® Invites You to Join Its Second Quarter Earnings Conference Call